A Phase 3 interventional study of Placebo administration and Confirm SARS-CoV-2 infection in Corona Virus Infection, Covid19 and SARS-CoV Infection, sponsored by MGC Pharmaceuticals d.o.o. Status unknown at 2 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-24.
Sponsored by MGC Pharmaceuticals d.o.o · Phase 3, Interventional, and Treatment
A preparation of CimertrA, comprising Artemisinin, Curcumin, and Boswellia, and Vitamin C in a nanoparticular formulation, is proposed as a treatment for the disease associated with the novel coronavirus SARS-CoV-2. This initiative is presented under the urgent circumstances of the fulminant pandemic caused by this lethal disease, which is known as COVID-19 and has spread across the globe causing death and disrupting the normal function of modern society. The grounds for the proposal are rooted in existing knowledge on the components and pharmacological features of this formulation and their relevance to the current understanding of the disease process being addressed.
The severe acute respiratory syndrome-associated coronavirus disease 2019 (COVID-19) illness results from the immediate response to the viral infection as well as from a subsequent host inflammatory response. Systemic proinflammatory cytokines and biomarkers are elevated as the disease progresses towards its advanced stages, and correlate with worse chances of survival.
Serum cytokine levels that are elevated in patients with Covid-19-associated cytokine storm include interleukin-1β, interleukin-6, IP-10, TNF, interferon-γ, macrophage inflammatory protein (MIP) 1α and 1β, and VEGF. Higher interleukin-6 levels are strongly associated with shorter survival. The relative frequencies of circulating activated CD4+ and CD8+ T cells and plasmablasts are increased in Covid-19. In addition to the elevated systemic cytokine levels and activated immune cells, several clinical and laboratory abnormalities, such as elevated CRP and d-dimer levels, hypoalbuminemia, renal dysfunction, and effusions, are also observed in Covid-19. Laboratory test results reflecting hyper inflammation and tissue damage were found to predict worsening outcomes in Covid-19.
CimetrA, comprising Artemisinin, Curcumin, Boswellia, and Vitamin C in a nanoparticular formulation, has been studied on patients with COVID-19 in a randomized double-blind control Phase II study (MGC-006 - under a previous product name - ArtemiC). The study product demonstrated excellent safety and efficacy profiles.
Experiments performed in vitro with CimetrA demonstrated the ability to reduce cytokine elevation in response to stimulation of human PBMC preparations.
The currently proposed Multi-center multinational-controlled study is designed to include 252 adult patients who suffer from moderate COVID-19 infection. Safety will be assessed through collection and analysis of adverse events, blood and urine laboratory assessments, and vital signs.
After the screening visit, the study drug will be administrated twice a day morning and evening (every 12 hours) during (day 1 and day 2) The patients will be randomized in 1:1:1 ratio to study drug (CimetrA) in addition to Standard of Care (Arm 1 (CimetrA-1) or Arm 2 (CimetrA-2)) or Placebo in addition to Standard of Care (Arm 3).
The study will take place during the patient's hospitalization due to a COVID-19 infection. The study will last up to 4 weeks, until the conclusion on day 28. In case of hospital discharge within the study period, follow-up will continue per protocol until day 28 wherever the subject will be located, performed via phone call or in-clinic, depending on the status of the patient and study schedule.
252 adult patients who suffer from COVID-19 infection and do not participate in any other clinical trial. The patient must not agree to participate in any new clinical study during the study duration. The study will take place during the patient's hospitalization due to a COVID-19 infection. The study will last up to 4 weeks, until the conclusion on day 28. In case of hospital discharge within the study period, follow-up will continue per protocol until day 28 wherever the subject will be located, performed via phone call or in-clinic, depending on the status of the patient and study schedule.
Day 1 Prior to engaging in any study procedures, the subject must meet the inclusion/exclusion criteria by history (which includes a signed declination), and review and sign an ICF. Following procedures will be performed during the visit -
Day 2
Days 3-6
Day 7
Days 8-13
Day 14
Day 21 (phone visit)
Day 28 - Follow Up (clinic visit)
6,688 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's planned enrollment of 252 is above the median of 120 across 4,201 interventional studies indexed under Infections.
Browse Infections studies →MGC Pharmaceuticals d.o.o is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
a total dose containing a combination of Artemisinin 12 mg, Curcumin 40 mg, Boswellia 30 mg, and Vitamin C 120 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
Diagnostic Test: Confirm SARS-CoV-2 infection · Procedure: Physical Examination · Procedure: Vital Signs · Diagnostic Test: Hematology blood test · Diagnostic Test: Biochemistry blood test · Other: NEWS score · Diagnostic Test: PK test · Diagnostic Test: blood test for inflammatory markers · Diagnostic Test: D-dimer test · Other: VAS scale · Diagnostic Test: Urine pregnancy test for women of childbearing potential · Procedure: ECG · Other: COVID-19-Impact on Quality of Life Questionnaire · Drug: CimetrA-1
a total dose containing a combination of Artemisinin 8.4 mg, Curcumin 28 mg, Boswellia 21 mg, and Vitamin C 84 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
Diagnostic Test: Confirm SARS-CoV-2 infection · Procedure: Physical Examination · Procedure: Vital Signs · Diagnostic Test: Hematology blood test · Diagnostic Test: Biochemistry blood test · Other: NEWS score · Diagnostic Test: PK test · Diagnostic Test: blood test for inflammatory markers · Diagnostic Test: D-dimer test · Other: VAS scale · Diagnostic Test: Urine pregnancy test for women of childbearing potential · Procedure: ECG · Other: COVID-19-Impact on Quality of Life Questionnaire · Drug: CimetrA-2
composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
Drug: Placebo administration · Diagnostic Test: Confirm SARS-CoV-2 infection · Procedure: Physical Examination · Procedure: Vital Signs · Diagnostic Test: Hematology blood test · Diagnostic Test: Biochemistry blood test · Other: NEWS score · Diagnostic Test: PK test · Diagnostic Test: blood test for inflammatory markers · Diagnostic Test: D-dimer test · Other: VAS scale · Diagnostic Test: Urine pregnancy test for women of childbearing potential · Procedure: ECG · Other: COVID-19-Impact on Quality of Life Questionnaire
patients will receive the placebo treatment in addition to Standard of Care
patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Also known as: Covid-19 test
patients will undergo a physical examination on days 1-14 and day 28
patient's vital signs will be measured on days 1-14 and day 28
patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
Also known as: blood tests
patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
Also known as: blood tests
patient's NEWS score will be evaluated on days 1-14 and day 28
Also known as: scoring
PK test will be performed on day 1 only (only in Brazil sites)
Also known as: pharmacokinetics
patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
Also known as: blood tests
patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
Also known as: blood tests
patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
Also known as: scoring
patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
Also known as: pregnancy test
patients will undergo an ECG examination on days 1, and day 28
patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
Also known as: CimetrA-1 drug administration
patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
Also known as: CimetrA- 2 drug administration
clinical improvement in treatment groups
Time to sustained clinical improvement, defined as a national Early Warning Score 2 (NEWS2) of 2 Maintained for 24 Hours in comparison to routine treatment (measured on days 7, 14, 28)
Time frame: up to 28 days
oxygen dependency
Number of participants with depending on oxygen supplementation through day 28 since onset of symptoms
Time frame: up to 28 days
change in inflammatory marker levels
Change in inflammatory marker levels - IL-6, IL-1β, IL-12, TNF α, IFN-γ, CRP, NLR (Neutrophil / Lymphocyte ratio) at days 1, 2, 4, 7, 14, 28
Time frame: up to day 28
effective dose determination
Definition of the active dose of CimetrA
Time frame: up to 28 days
Pharmacokinetic profile
Pharmacokinetic profile of the study drug-AUC(mmol/L·h)
Time frame: up to 28 days
Pharmacokinetic profile
Pharmacokinetic profile of the study drug-Tmax (Hour)
Time frame: up to 28 days
Pharmacokinetic profile
Pharmacokinetic profile of the study drug-Cmax (mmol/L)
Time frame: up to 28 days
Incidence of mechanical ventilation
Incidence of mechanical ventilation
Time frame: up to 28 days
Incidence of Intensive Care Unit (ICU) stay during COVID-19 complication
Incidence of Intensive Care Unit (ICU) stay during COVID-19 complication
Time frame: up to 28 days
evaluation of drug related adverse events
Percentage of participants with definite or probable drug related adverse events
Time frame: up to 28 days
Long term adverse events of COVID-19
Long term adverse events of COVID-19 on Day 28
Time frame: up to 28 days
Quality of life of patients
Quality of life of patients on Days 0, 14 and 28. COVID-19 - Impact on Quality of Life (COV19-QoL) scale questionnaire. The scale was made in order to serve as a tool for controlling the impact of the situation with the COVID19 pandemic in general on findings of various research on mental health.The higher score, the greater impact on quality of life and related domains subjectively perceived by the participants. Scores could be displayed and analyzed for each item separately. recommend the following way of calculating the total score for each participant: summing the scores on all of the items and dividing that result by the number of items (i.e. 6). Hence, the total score will be the average of all the items. The average score is measured between 1-5 scale.
Time frame: up to 28 days
Duration of mechanical ventilation
Duration of mechanical ventilation
Time frame: up to day 28
Course of change in D Dimer levels compared to baseline
Time frame: up to 28 days
Occurrence of secondary infections
Time frame: up to 28 days
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MGC Pharmaceuticals d.o.o